文献速递肝病消化道肿瘤与早癌

肝硬化患者对肝细胞癌监测参数的偏好

Patient Preferences for Hepatocellular Carcinoma Surveillance Parameters.
PubMed 文献 · Clin Gastroenterol Hepatol · 2021-02-19

该研究在四家机构对肝硬化患者进行基于选择的联合分析调查,评估其对肝细胞癌监测方式的偏好。结果显示监测获益重要性占51.3%,患者更偏好简化MRI、MRI或新型血液生物标志物,而非超声联合或不联合AFP。

要点

  • 肝硬化患者将早期HCC检测获益视为监测选择的最重要属性。
  • 患者对简化MRI和血液生物标志物的偏好高于超声联合或不联合AFP。
  • 患者对监测相关身体伤害和费用的重视程度相对较低。

核心结论

  • 肝硬化患者优先考虑早期HCC检测,而非监测相关的潜在伤害或不便。

研究设计与样本

  • 在四家机构对肝硬化患者进行的基于选择的联合分析调查。
  • 199名被接触患者中182名同意参与,179名完成调查。
  • 参与者需在15个场景中基于五项测试属性选择监测方式。

主要发现

  • 监测获益重要性为51.3%(95%CI 49.0-53.4%),高于身体伤害风险7.6%(95%CI 7.0-8.2%)、财务伤害15.2%(95%CI 14.0-16.3%)、便利性9.3%(95%CI 8.5-10.1%)和测试物流16.7%(95%CI 15.4-18.1%)。
  • 模拟显示患者偏好简化MRI(29.0%)、MRI(23.3%)或新型血液生物标志物(20.9%),高于单独超声(3.4%)或超声联合AFP(8.8%)。

关键数值与推荐

  • 测试属性包括早期HCC敏感性范围35-95%、需额外检测的假阳性范围10-40%、自付费用范围10-100美元、测试时长范围10-60分钟。

临床怎么用

  • 临床选择HCC监测方式时应充分考虑患者对早期检测获益的高度重视。
  • 简化MRI和血液生物标志物可能因患者偏好而具有更高的接受度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Professional societies recommend abdominal ultrasound (US) with or without alpha fetoprotein (AFP) for hepatocellular cancer (HCC) surveillance; however, there are several emerging surveillance modalities, including abbreviated MRI and blood-based biomarker panels. Most studies have focused on provider perspectives for surveillance logistics, but few have assessed patient preferences. We aimed to measure preferences among patients with cirrhosis regarding HCC surveillance modalities. METHODS: We conducted a choice-based conjoint survey to patients with cirrhosis at four institutions. Participants were provided 15 scenarios in which they were asked to choose surveillance modalities based on five test attributes: benefits, i.e. sensitivity for early HCC (range: 35-95%), physical harm, i.e. false positives requiring additional testing (range: 10-40%), financial harm, i.e. out-of-pocket costs (range: $10-100), test logistics and convenience, i.e. duration of testing (range: 10-60 min). Hierarchical Bayes discrete choice conjoint analysis was used to derive attribute importance, and preference shares were determined by simulation. RESULTS: In total 91% (182/199) of approached patients consented to participate in the study and 98% (n=179) successfully completed the survey. Surveillance benefits (importance: 51.3%, 95%CI: 49.0-53.4%) were valued more than risk of physical harm (importance: 7.6%, 95%CI 7.0-8.2%), financial harm (importance: 15.2%, 95%CI 14.0-16.3%), convenience (importance: 9.3%, 95%CI 8.5-10.1%) and test logistics (importance: 16.7%, 95%CI 15.4-18.1%). Based on simulations including all possible tests, patients preferred abbreviated MRI (29.0%), MRI (23.3%), or novel blood-based biomarkers (20.9%) to ultrasound alone (3.4%) or with AFP (8.8%). CONCLUSIONS: Patients with cirrhosis prioritize early HCC detection over potential surveillance-related harms or inconvenience.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Woolen SA, Singal AG, Davenport MS, et al. Patient Preferences for Hepatocellular Carcinoma Surveillance Parameters. Clin Gastroenterol Hepatol. 2021. PMID: 33618022. doi:10.1016/j.cgh.2021.02.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。